MED12 mutation as a potential predictive biomarker for immune checkpoint inhibitors in pan-cancer
Abstract Immune checkpoint inhibitors (ICIs) therapy elicits admirable anti-tumor responses across many types of cancer. Growing evidence point to a link to Mediator complex subunit 12 (MED12) and DNA damage repair (DDR) and TGF-β signing, while the clinical data on the association of MED12 and ICIs...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMC
2022-10-01
|
| シリーズ: | European Journal of Medical Research |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s40001-022-00856-z |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|